Cargando…
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial
Adolescents and children play an important role in SARS-CoV-2 transmission and epidemiology. MVC-COV1901 is a subunit SARS-CoV-2 vaccine based on stabilized spike protein adjuvanted with CpG 1018 and aluminum hydroxide that has received emergency use approval (EUA) for adults in Taiwan. In this stud...
Autores principales: | Liu, Luke Tzu-Chi, Chiu, Cheng-Hsun, Chiu, Nan-Chang, Tan, Boon-Fatt, Lin, Chien-Yu, Cheng, Hao-Yuan, Lin, Meei-Yun, Lien, Chia-En, Chen, Charles, Huang, Li-Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755761/ https://www.ncbi.nlm.nih.gov/pubmed/36526640 http://dx.doi.org/10.1038/s41541-022-00589-4 |
Ejemplares similares
-
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
por: Waits, Alexander, et al.
Publicado: (2022) -
A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV
por: Cheng, Shu-Hsing, et al.
Publicado: (2022) -
Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine
por: Lin, Yi-Jiun, et al.
Publicado: (2022) -
An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay
por: Torales, Julio, et al.
Publicado: (2023) -
Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222
por: Cheng, Shu-Hsing, et al.
Publicado: (2022)